Genfit makes $135M debut on Nasdaq
The French company, developing a drug to treat nonalcoholic steatohepatitis, or NASH, announced the pricing of its shares at $20.32 apiece.
The French company, developing a drug to treat nonalcoholic steatohepatitis, or NASH, announced the pricing of its shares at $20.32 apiece.
Prior to founding health benefits platform Jiff (which was acquired by Castlight in 2017), Newell worked for years in the remote care monitoring and chronic disease management space.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
The company joins a growing wave of firms developing drugs for the disease, which has no approved treatments. It expects to enter two drugs into the clinic next year.
The companies will run clinical trials combining Novartis' tropifexor with any one of several Pfizer drugs under development for the disease, which lacks approved treatments.
The new company is headquartered in San Francisco, with R&D in Israel and has launched a Phase I study of BIO89-100, formerly TEV-47948.
The company secured $60 million in a Series A round from Third Rock and Takeda, plus a partnership with Takeda.